• Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal- and luminal-like breast cancer xenografts 

      Lindholm, Evita Maria; Kristian, Alexandr; Nalwoga, Hawa; Kruger, Kristi; Nygård, Ståle; Akslen, Lars A.; Mælandsmo, Gunhild (Journal article; Tidsskriftartikkel; Peer reviewed, 2012-03-31)
      Several clinical trials have investigated the efficacy of bevacizumab in breast cancer, and even if growth inhibiting effects have been registered when antiangiogenic treatment is given in combination with chemotherapy no gain in overall survival has been observed. One reason for the lack of overall survival benefit might be that appropriate criteria for selection of patients likely to respond ...
    • Subtype-specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts 

      Borgan, Eldrid; Lindholm, Evita Maria; Moestue, Siver Andreas; Mælandsmo, Gunhild; Lingjærde, Ole Christian; Gribbestad, Ingrid S; Børresen-Dale, Anne-Lise; Engebråten, Olav; Sørlie, Therese (Journal article; Tidsskriftartikkel; Peer reviewed, 2012-10-23)
      <p>Antiangiogenic therapy with bevacizumab has shown varying results in breast cancer clinical trials. Identifying robust biomarkers for selecting patients who may benefit from such treatment and for monitoring response is important for the future use of bevacizumab.</p> <p>Two established xenograft models representing basal‐like and luminal‐like breast cancer were used to study bevacizumab ...